Stichprovokation

Ruëff, Franziska; Przybilla, Bernhard

doi:10.1007/s00105-014-2779-2

Cited by 11 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite these findings, up to date no biomarker for the evaluation of VIT efficacy has been established. Therefore, a controlled insect sting challenge remains the golden standard for the evaluation of venom tolerance, indicating clinical protection in humans [11,36,37]. In this study, 3 out of 10 dog owners refused a controlled sting challenge, which is in line with human data [14].…”

Section: Discussionsupporting

confidence: 55%

See 1 more Smart Citation

Hymenoptera Venom Immunotherapy in Dogs: Safety and Clinical Efficacy

Rostaher,

Fischer,

Vigani

et al. 2023

Animals

View full text Add to dashboard Cite

Hymenoptera allergens are the main triggers for anaphylaxis in susceptible dogs and humans. Hymenoptera venom specific immunotherapy (VIT), the only disease-modifying treatment, has the potential to prevent future life-threatening reactions in human patients. Prospective clinical data on VIT efficacy in dogs are currently lacking. Therefore, the aim of this study was to show that VIT is not only safe but also efficacious in preventing anaphylaxis in dogs allergic to Hymenoptera. This uncontrolled prospective clinical trial included 10 client-owned dogs with a history of anaphylaxis following repeated Hymenoptera stings. The sensitization to bee and wasp allergens was demonstrated by intradermal testing (IDT) and allergen-specific IgE serology. For VIT induction (induction phase), dogs received a shortened rush immunotherapy protocol with aqueous allergens, which was then followed by monthly injections of 100 µg of alum-precipitated allergen (maintenance phase). VIT efficacy was determined by observing patients’ clinical reactions to re-stings. No systemic adverse events were seen during the induction and maintenance phases. From the seven re-stung dogs, only one developed a mild angioedema at the site of the sting; the remaining dogs were asymptomatic. These results show that VIT represents a safe and effective treatment option for Hymenoptera-allergic dogs.

show abstract

Section: Discussionsupporting

confidence: 55%

“…The efficacy was determined either by accidentally occurring stings, or an in-clinic challenge after 6 months (Figure 2), as published previously for humans undergoing VIT [26]. For the in-clinic challenge, the insect used was entomologically identified.…”

Section: Safety and Efficacy Evaluationmentioning

confidence: 99%

Hymenoptera Venom Immunotherapy in Dogs: Safety and Clinical Efficacy

Rostaher,

Fischer,

Vigani

et al. 2023

Animals

View full text Add to dashboard Cite

show abstract

“… 10 According to recommendations, it should be performed 6–18 months after the maintenance dose has been reached, in order to identify non-responders to VIT. 16 In case of a non-response, presented by a systemic allergic reaction to the SC, an increase of the maintenance dose is advised. 10 Risk factors for treatment failure include systemic reactions during VIT, allergy to bee venom, systemic mastocytosis, and elevated serum tryptase levels, as well as concomitant medication with inhibitors of the angiotensin-converting enzyme.…”

Section: Introductionmentioning

confidence: 99%

“… 17 However, a SC should neither be performed before VIT is started nor routinely after a completed course, in order to avoid boosting the allergy. 16 Other absolute contraindications for a SC include severe and uncontrolled systemic diseases (eg, bronchial asthma, hypertension), pregnancy, and/or recurrent systemic reactions during the maintenance period just before the planned SC. 16 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy

Eitel

Zeiner

Aßmus

et al. 2021

World Allergy Organization Journal

View full text Add to dashboard Cite

Background An experienced life-threating anaphylactic reaction to hymenoptera venom can sustainably impair patients’ quality of life (QoL). Besides carrying emergency medication, venom-specific immunotherapy (VIT) exists as a causal treatment of allergy. Objective This study aimed to examine QoL, anxiety, depression, and physical and mental health in patients allergic to hymenoptera venom before and during VIT and the impact of a tolerated sting challenge (SC). Methods Between July 2017 and August 2017, 142 patients with venom allergy were analyzed using validated questionnaires as the: Vespid Allergy Quality for Life Questionnaire" (VQLQ-d), the "Hospital Anxiety and Depression Scale" (HADS-D) and the "Short Form 36" (SF-36). To evaluate the impact of VIT and SC on the QoL, patients were divided into 3 groups: (A) VIT and tolerated SC (n = 45), (B) VIT before carrying out SC (n = 73), and (C) therapy-naïve before VIT (n = 20). Further parameters like gender, age, insect species, and severity of the anaphylactic reaction were assessed. Results A significant correlation between the health-related QoL and the parameters of gender and state of treatment was seen. Especially male patients, as well as patients allergic to yellow jacket venom, benefit from a SC in terms of a significant increase in their QoL. In the total study cohort, a clear trend was observed towards a higher QoL in patients under VIT who tolerated a SC. Overall, neither the patients’ age nor the insect species exerted a relevant influence on QoL, depression or anxiety. However, women showed a lower QoL combined with higher anxiety and depression scores than men. Conclusion Immunotherapy leads to an improved QoL, which can be further increased by a SC. A tolerated SC conceivably reassures the patients by objectifying the treatment success. Female patients appear to have a stronger impaired QoL per se. Taken together, a SC can be performed during VIT to strengthen the patients’ QoL.

show abstract

Insektenstichprovokationen

Przybilla¹,

Ruëff²

2016

Allergologie

View full text Add to dashboard Cite

Stichprovokation

Cited by 11 publications

References 22 publications

Hymenoptera Venom Immunotherapy in Dogs: Safety and Clinical Efficacy

Hymenoptera Venom Immunotherapy in Dogs: Safety and Clinical Efficacy

Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy

Insektenstichprovokationen

Contact Info

Product

Resources

About